IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2020-11, Vol.69 (11), p.2371-2380
• Main Authors: Zheng, Yujia, Li, Yu, Tang, Bo, Zhao, Qitai, Wang, Dan, Liu, Yulin, Guo, Mengxing, Zhao, Song, Qi, Yu, Zhang, Yi, Huang, Lan
• Format: Article
• Language: English
• Subjects: Apyrase - biosynthesis; Apyrase - immunology; Cancer Research; Esophageal Neoplasms - immunology; Esophageal Squamous Cell Carcinoma - immunology; Female; Humans; Immunology; Interleukin-6 - immunology; Interleukin-6 - metabolism; Killer Cells, Natural - immunology; Killer Cells, Natural - metabolism; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Male; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Prognosis; Tumor Escape - immunology; Tumor Microenvironment - immunology
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-020-02629-1

Natural killer (NK) cells, a predominant innate lymphocyte subset, mediates eradicating malignant cells. Purinergic signaling by ectonucleotidase CD39 can suppress T-cell response in caner. However, the role of CD39 in NK cells has not been fully elucidated. Here, we characterized CD39 expression on NK cells and its clinical relevance in esophageal squamous cell carcinoma (ESCC). Peripheral blood and tissue samples were collected from 36 ESCC patients. We observed that the proportion of NK cells significantly decreased but CD39 was obviously up-regulated on NK cells from cancerous tissues compared to paired peripheral blood in ESCC patients. Furthermore, tumor-infiltrating NK cells with high CD39 expression exhibited a phenotype of functional impairment. In vitro, conditioned media of ESCC cell lines could induce CD39 expression on peripheral NK cells from healthy donors. IL-6 was identified as the major cytokine produced by ESCC cell lines and also elevated in both tumor tissues and blood serum from ESCC patients. Recombinant IL-6 significantly induced surface CD39 expression in human NK cells, while IL-6-receptor antagonist tocilizumab prevented this effect. Finally, tumor-infiltrating CD39 + NK cells were correlated with poor prognosis in ESCC patients. Thus, tumor-derived IL-6 might impair NK cell functions through induction of CD39 expression. CD39 + NK cells may serve as a potential prognostic biomarker for ESCC patients.